4.7 Review

Non-coding RNAs in cancer: platforms and strategies for investigating the genomic dark matter

出版社

BMC
DOI: 10.1186/s13046-020-01622-x

关键词

Cancer genetics; Non-coding RNAs; microRNAs; miRNAs; Long-non coding RNAs; lncRNAs; ncRNA functions

类别

资金

  1. Italian Association for Cancer Research (AIRC) Investigator Grant Small molecule-based targeting of lncRNAs 3D structure: a translational platform for treatment of multiple myeloma [21588]
  2. AIRC Special Program for Molecular Clinical Oncology-5 per mille 2010-15 and its Extension Program 2016-18 [9980]
  3. CARICAL foundation microRNA-based immunotherapeutic strategies for Multiple Myeloma and Chronic Lymphocytic Leukemia [16695]

向作者/读者索取更多资源

The discovery of the role of non-coding RNAs (ncRNAs) in the onset and progression of malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are candidates for therapeutic intervention, since they may act as biomarkers or key regulators of cancer gene network. Recently, profiling and sequencing of ncRNAs disclosed deep deregulation in human cancers mostly due to aberrant mechanisms of ncRNAs biogenesis, such as amplification, deletion, abnormal epigenetic or transcriptional regulation. Although dysregulated ncRNAs may promote hallmarks of cancer as oncogenes or antagonize them as tumor suppressors, the mechanisms behind these events remain to be clarified. The development of new bioinformatic tools as well as novel molecular technologies is a challenging opportunity to disclose the role of the dark matter of the genome. In this review, we focus on currently available platforms, computational analyses and experimental strategies to investigate ncRNAs in cancer. We highlight the differences among experimental approaches aimed to dissect miRNAs and lncRNAs, which are the most studied ncRNAs. These two classes indeed need different investigation taking into account their intrinsic characteristics, such as length, structures and also the interacting molecules. Finally, we discuss the relevance of ncRNAs in clinical practice by considering promises and challenges behind the bench to bedside translation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics

Nicoletta Staropoli, Mariamena Arbitrio, Angela Salvino, Francesca Scionti, Domenico Ciliberto, Rossana Ingargiola, Caterina Labanca, Giuseppe Agapito, Eleonora Iuliano, Vito Barbieri, Maria Cuce, Valeria Zuccala, Mario Cannataro, Pierfrancesco Tassone, Pierosandro Tagliaferri

Summary: This study aimed to identify biomarkers predictive of platinum-response in ovarian cancer patients. The results showed that the UGT2A1 gene may play an important role in predicting platinum-response and prognosis.

BIOMEDICINES (2022)

Article Chemistry, Multidisciplinary

MedChemBlog: An Innovative Distance Learning Experience for Teaching Medicinal Chemistry

Giulia Panzarella, Gianmarco Gualtieri, Isabella Romeo, Stefano Alcaro

Summary: A qualified teaching method is difficult to achieve without traditional classroom lessons. However, in this innovative distance learning experiment, students have been able to change traditional teaching methods by creating a multimedia tool called MedChemBlog, which has improved their understanding of chemical structures and drug molecular mechanisms.

JOURNAL OF CHEMICAL EDUCATION (2023)

Article Biochemistry & Molecular Biology

Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands

Maria Dichiara, Francesca Alessandra Ambrosio, Carla Barbaraci, Rafael Gonzalez-Cano, Giosue Costa, Carmela Parenti, Agostino Marrazzo, Lorella Pasquinucci, Enrique J. Cobos, Stefano Alcaro, Emanuele Amata

Summary: The development of diazabicyclo[4.3.0]nonane and 2,7-diazaspiro[3.5]nonane derivatives as sigma receptors (SRs) ligands is discussed. The compounds were evaluated for their binding to S1R and S2R, and modeling studies were conducted to analyze the binding mode. Three notable compounds, 4b, 5b, and 8f, were further tested for their analgesic effects and functional profiles. Compound 4b showed S1R agonistic effects, while compounds 5b and 8f exhibited S1R antagonism.

ACS CHEMICAL NEUROSCIENCE (2023)

Article Chemistry, Medicinal

Hit identification of novel small molecules interfering with MALAT1 triplex by a structure-based virtual screening

Roberta Rocca, Nicoletta Polera, Giada Juli, Katia Grillone, Annalisa Maruca, Maria Teresa Di Martino, Anna Artese, Jussara Amato, Bruno Pagano, Antonio Randazzo, Pietrosandro Tagliaferri, Pierfrancesco Tassone, Stefano Alcaro

Summary: RNA is currently a target of interest for the design of new small molecules with diverse pharmacological activities. Among these RNA molecules, long noncoding RNAs (lncRNAs) have been extensively associated with cancer pathogenesis. In particular, the overexpression of lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) plays a crucial role in the development of multiple myeloma (MM). By utilizing the crystallographic structure of the triple-helical stability element of MALAT1, a structure-based virtual screening was conducted on a large commercial database, and five compounds were selected for in vitro assays. Among them, compound M5 showed the most promising results, destabilizing the MALAT1 triplex structure and demonstrating antiproliferative activity in MM cell models. M5 is suggested as a lead compound for further optimization to enhance its affinity towards MALAT1.

ARCHIV DER PHARMAZIE (2023)

Article Biochemistry & Molecular Biology

HSV-1 Glycoprotein D and Its Surface Receptors: Evaluation of Protein-Protein Interaction and Targeting by Triazole-Based Compounds through In Silico Approaches

Roberta Bivacqua, Isabella Romeo, Marilia Barreca, Paola Barraja, Stefano Alcaro, Alessandra Montalbano

Summary: Protein-protein interactions are an attractive target for drug design. This study focuses on the HSV-1 envelope glycoprotein D (gD) and identifies potential inhibitors for gD through protein-protein docking, dynamic simulations, and virtual screening. Four triazolo[4,5-b]pyridines are found to have good theoretical affinity towards all conformations of HSV-1 gD. This study provides a promising basis for the design of new antiviral agents targeting gD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma

Francesca Scionti, Giada Juli, Roberta Rocca, Nicoletta Polera, Matteo Nadai, Katia Grillone, Daniele Caracciolo, Caterina Riillo, Emanuela Altomare, Serena Ascrizzi, Basilio Caparello, Maria Cerra, Mariamena Arbitrio, Sara N. N. Richter, Anna Artese, Stefano Alcaro, Pierosandro Tagliaferri, Pierfrancesco Tassone, Maria Teresa Di Martino

Summary: In this study, the researchers found that a small molecule called hit 17 could stabilize the structure of TERRA, causing the dissociation of TRF2 from telomeres in multiple myeloma (MM) cell lines. This led to activation of the DNA damage response, cell cycle arrest, proliferation block, and apoptotic death. Furthermore, hit 17 demonstrated anti-tumor activity in MM xenograft models.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Medicine, Research & Experimental

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer

Caterina Riillo, Nicoletta Polera, Maria Teresa Di Martino, Giada Juli, Craig A. Hokanson, Tatjana Odineca, Stefania Signorelli, Katia Grillone, Serena Ascrizzi, Antonia Mancuso, Nicoletta Staropoli, Basilio Caparello, Maria Cerra, Giuseppe Nistico, Pierosandro Tagliaferri, Roberto Crea, Daniele Caracciolo, Pierfrancesco Tassone

Summary: This study describes the activity of a new class of antibody mimics called Pronectins (TM) against Epithelial Ovarian Cancer (EOC). The Pronectins can activate T lymphocytes to kill EOC cells, and their cytotoxicity can be enhanced by combining with PARPi. In mouse models, this therapy effectively inhibits the growth of EOC tumors and prolongs the survival of the mice. This study provides a rationale for the development of Pronectins as a novel treatment for EOC and demonstrates the potential of this new immune therapeutic approach in cancer treatment.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Article Biochemistry & Molecular Biology

Uncovering Novel Capsaicin Inhibitory Activity towards Human Carbonic Anhydrase Isoforms IX and XII by Combining In Silico and In Vitro Studies

Gianmarco Gualtieri, Annalisa Maruca, Roberta Rocca, Fabrizio Carta, Emanuela Berrino, Alessandro Salatino, Carolina Brescia, Roberta Torcasio, Manuel Crispo, Francesco Trapasso, Stefano Alcaro, Claudiu T. Supuran, Giosue Costa

Summary: Capsaicin, a bioactive spicy molecule found in hot peppers, has been extensively studied for its beneficial effects. This study used in silico methods to evaluate its inhibitory activity against tumor-associated human CA IX and XII. In vitro assays confirmed its inhibitory activity, and a non-small cell lung cancer model showed that Capsaicin can inhibit cell migration.

ANTIOXIDANTS (2023)

Article Biochemistry & Molecular Biology

An Uncharacterised lncRNA Coded by the ASAP1 Locus Is Downregulated in Serum of Type 2 Diabetes Mellitus Patients

Cristina Barbagallo, Michele Stella, Stefania Di Mauro, Alessandra Scamporrino, Agnese Filippello, Francesca Scionti, Maria Teresa Di Martino, Michele Purrello, Marco Ragusa, Francesco Purrello, Salvatore Piro

Summary: Diabetes mellitus (DM) is a complex disease characterized by high blood glucose levels. Type 2 Diabetes (T2D) is the most common form, affecting middle-aged or elderly individuals and its incidence is increasing among children and adults. This study analyzed the transcriptome of serum samples from T2D patients and identified a long non-coding RNA (lncRNA) as a potential diagnostic biomarker. The combination of this lncRNA with clinical parameters showed better diagnostic performance than the glycated haemoglobin test. Using this biomarker in clinical practice would improve the diagnosis and management of T2D patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

Pierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, Lucia Fiorillo, Nicoletta Staropoli, Domenico Ciliberto, Alessia Cordua, Francesca Scionti, Bernardo Bertucci, Angela Salvino, Mariangela Lopreiato, Fredrik Thunarf, Onofrio Cuomo, Maria Cristina Zito, Maria Rosanna De Fina, Amelia Brescia, Simona Gualtieri, Caterina Riillo, Francesco Manti, Daniele Caracciolo, Vito Barbieri, Eugenio Donato Di Paola, Adele Emanuela Di Francesco, Pierosandro Tagliaferri

Summary: We developed an LNA-i-miR-221 inhibitor that downregulated miR-221 and showed anti-tumor activity in mice. The drug was well tolerated in patients and the recommended phase II dose was determined to be 5 mg/kg.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Article Chemistry, Medicinal

Identification of HuR-RNA Interfering Compounds by Dynamic Combinatorial Chemistry and Fluorescence Polarization

Serena Della Volpe, Roberta Listro, Francesca Alessandra Ambrosio, Martina Garbagnoli, Pasquale Linciano, Daniela Rossi, Giosue Costa, Stefano Alcaro, Francesca Vasile, Anna K. H. Hirsch, Simona Collina

Summary: RNA binding protein HuR plays a role in the regulation of oncogenes and tumor suppressor genes, and its dysregulation is associated with cancer. This study utilized protein-templated dynamic combinatorial chemistry to search for novel HuR ligands that can interfere with the HuR-RNA complex. Several compounds were identified and shown to effectively interfere with HuR-RNA binding, indicating their potential as anticancer agents targeting HuR-RNA interactions.

ACS MEDICINAL CHEMISTRY LETTERS (2023)

Review Oncology

Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice

Serena Ascrizzi, Grazia Maria Arillotta, Katia Grillone, Giulio Carida, Stefania Signorelli, Asad Ali, Caterina Romeo, Pierfrancesco Tassone, Pierosandro Tagliaferri

Summary: Lynch syndrome, also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC), is an autosomal dominant cancer syndrome that poses a high risk of developing colorectal and endometrial cancer. The molecular mechanisms underlying Lynch syndrome, including microsatellite instability and miRNA modulation, have attracted significant interest. This review discusses the management of Lynch syndrome patients and highlights the importance of microRNAs as potential biomarkers and therapeutic targets for novel clinical approaches.

CANCERS (2023)

Article Chemistry, Medicinal

Molecular and Structural Aspects of Clinically Relevant Mutations of SARS-CoV-2 RNA-Dependent RNA Polymerase in Remdesivir-Treated Patients

Carmen Gratteri, Francesca Alessandra Ambrosio, Antonio Lupia, Federica Moraca, Bruno Catalanotti, Giosue Costa, Maria Bellocchi, Luca Carioti, Romina Salpini, Francesca Ceccherini-Silberstein, Simone La Frazia, Vincenzo Malagnino, Loredana Sarmati, Valentina Svicher, Sharon Bryant, Anna Artese, Stefano Alcaro

Summary: This study evaluated the impact of RdRp mutations on the efficacy of remdesivir in treating COVID-19. Clinical observations revealed that patients with specific mutations showed a reduced response to remdesivir, accompanied by an increase in viral load and a decrease in binding affinity to RdRp. Computational approaches helped to explain these clinical observations by analyzing the effects of mutants on the viral RNA synthesis machine and the binding patterns of remdesivir.

PHARMACEUTICALS (2023)

Review Multidisciplinary Sciences

First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis

Domenico Ciliberto, Giulio Carid, Nicoletta Staropoli, Caterina Romeo, Grazia Maria Arillotta, Cristina Napoli, Luigia Gervasi, Francesco Luciano, Caterina Riillo, Pierfrancesco Tassone, Pierosandro Tagliaferri

Summary: The rational choice of systemic upfront treatment for advanced hepatocellular carcinoma has become uncertain due to the rapid development of novel therapeutic options. Various therapeutic strategies, including the combination of immune checkpoint inhibitors and anti-VEGF, have been investigated. A systematic review and meta-analysis of randomized clinical trials were conducted to compare the efficacy and toxicity of these strategies. The combination of Camrelizumab + Rivoceranib ranked highest in overall survival, followed by Sintilimab + Bevacizumab, while Lenvatinib + Pembrolizumab showed greater probability of being the best in progression-free survival and Sintilimab + Bevacizumab performed best in overall response rate. Durvalumab was found to be the most tolerated treatment.

HELIYON (2023)

暂无数据